What is B. Riley’s Estimate for AVBP Q1 Earnings?

ArriVent BioPharma, Inc. (NASDAQ:AVBP) – Analysts at B. Riley issued their Q1 2025 EPS estimates for shares of ArriVent BioPharma in a research note issued to investors on Wednesday, March 19th. B. Riley analyst K. Patel expects that the company will post earnings of ($0.70) per share for the quarter. B. Riley has a “Strong-Buy” rating on the stock. The consensus estimate for ArriVent BioPharma’s current full-year earnings is ($2.74) per share. B. Riley also issued estimates for ArriVent BioPharma’s Q2 2025 earnings at ($0.76) EPS, Q3 2025 earnings at ($0.86) EPS, Q4 2025 earnings at ($0.97) EPS, FY2025 earnings at ($3.30) EPS, FY2026 earnings at ($4.64) EPS, FY2027 earnings at ($3.52) EPS, FY2028 earnings at ($1.75) EPS and FY2029 earnings at $0.40 EPS.

ArriVent BioPharma (NASDAQ:AVBP) last posted its quarterly earnings data on Monday, March 3rd. The company reported ($0.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.18.

A number of other research firms also recently commented on AVBP. HC Wainwright reaffirmed a “buy” rating and set a $39.00 price objective on shares of ArriVent BioPharma in a report on Friday, March 7th. Guggenheim started coverage on ArriVent BioPharma in a report on Monday, March 10th. They set a “buy” rating and a $45.00 price objective on the stock. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $39.00.

ArriVent BioPharma Price Performance

AVBP opened at $18.99 on Monday. The company has a market capitalization of $645.96 million, a P/E ratio of -7.39 and a beta of 1.00. The firm’s fifty day moving average price is $24.70 and its two-hundred day moving average price is $26.62. ArriVent BioPharma has a fifty-two week low of $14.35 and a fifty-two week high of $36.37.

Institutional Trading of ArriVent BioPharma

Hedge funds have recently modified their holdings of the company. Charles Schwab Investment Management Inc. grew its position in ArriVent BioPharma by 153.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 202,368 shares of the company’s stock worth $4,756,000 after acquiring an additional 122,641 shares during the last quarter. Geode Capital Management LLC increased its position in ArriVent BioPharma by 154.2% in the 3rd quarter. Geode Capital Management LLC now owns 597,165 shares of the company’s stock valued at $14,036,000 after acquiring an additional 362,221 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of ArriVent BioPharma in the fourth quarter worth about $31,000. Barclays PLC lifted its position in shares of ArriVent BioPharma by 1,124.8% during the third quarter. Barclays PLC now owns 41,522 shares of the company’s stock worth $976,000 after purchasing an additional 38,132 shares in the last quarter. Finally, State Street Corp grew its stake in shares of ArriVent BioPharma by 210.4% during the third quarter. State Street Corp now owns 476,809 shares of the company’s stock valued at $11,205,000 after purchasing an additional 323,186 shares during the last quarter. Institutional investors and hedge funds own 9.48% of the company’s stock.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.